Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brandi Addison

Endocrinology, Diabetes & Metabolism Corpus Christi, TX Doctor of Osteopathy

NPI 1891115275 CMS profile 958176

7121 S Padre Island Dr Ste 300, Corpus Christi, TX 78412

Open in the dashboard

General payments

$646,952

1,523 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,908 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Brandi Addison of Corpus Christi, TX is reported in the CMS Open Payments database as having received $646,952 across 1,523 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,908 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147,366 265
2024 General $139,869 280
2023 General $95,192 260
2022 General $103,916 171
2021 General $84,603 194
2020 General $61,763 218
2019 General $14,242 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandi Addison
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Brandi Addison were reported at $147,366. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Brandi Addison Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $14,242 $494 $123–$2,253 $163
2020 $61,763 $335 $85–$1,841 $114
2021 $84,603 $398 $88–$1,981 $132
2022 $103,916 $364 $88–$1,568 $149
2023 $95,192 $420 $113–$1,614 $160
2024 $139,869 $440 $121–$1,646 $164
2025 $147,366 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $330,392 565 payments
  2. Corcept Therapeutics $149,658 215 payments
  3. Novo Nordisk Inc $97,569 214 payments
  4. Eli Lilly and Company $18,121 30 payments
  5. Sanofi-Aventis U.S. LLC $18,030 97 payments
  6. AstraZeneca Pharmaceuticals LP $17,784 49 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $9,001 54 payments
  8. Amgen Inc. $838 42 payments
  9. Dexcom, Inc. $460 25 payments
  10. Senseonics, Incorporated $400 1 payment
  11. Other $4,697 231 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $521,080 472 payments
  2. Travel and Lodging $51,638 115 payments
  3. Consulting Fee $35,347 15 payments
  4. Food and Beverage $23,538 908 payments
  5. Honoraria $15,175 6 payments
  6. Education $175 7 payments
Products named General payments · program years 2019–2025
  1. Korlym $149,658 215 payments
  2. ZEPBOUND $135,874 171 payments
  3. MOUNJARO $108,507 186 payments
  4. TRULICITY $63,826 116 payments
  5. Wegovy $53,085 83 payments
  6. Saxenda $35,885 66 payments
  7. FARXIGA $17,784 49 payments
  8. JARDIANCE Diabetes $8,788 44 payments
  9. JARDIANCE Diabetes $7,585 38 payments
  10. TOUJEO $4,979 16 payments
  11. Other $23,657 704 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

3,078

Median for Endocrinology: 1,959

Drug cost

$3,299,589

Median for Endocrinology: $890,201

Branded share of claims

67.9%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Korlym Mifepristone Brand 35 $1,192,867
Mounjaro Tirzepatide Brand 577 $755,007
Ozempic Semaglutide Brand 187 $239,628
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 170 $222,263
Jardiance Empagliflozin Brand 165 $189,631
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 133 $134,251
Trulicity Dulaglutide Brand 88 $125,140
Farxiga Dapagliflozin Propanediol Brand 71 $76,230
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 52 $58,551
Synjardy Xr Empagliflozin/Metformin Hcl Brand 49 $55,858

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$103,495

Medicare's payments for the services billed

Medicare patients

349

Average age 71

Services billed

1,556

221 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 71%
Arthritis 47%
Chronic kidney disease 38%
Ischemic heart disease 32%
Depression 23%
Heart failure 16%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
$56,849 — —
Korlym
$34,699 35 —
Wegovy
$21,621 — —
MOUNJARO
$8,189 577 —
Kerendia
$203 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

1,523 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record